Cardiogenic shock (CS) is a complex multifactorial clinical syndrome with extremely high
mortality, developing as a continuum, and progressing from the initial insult (underlying cause) …

… Early revascularization as shown in the SHould we emergently revascularize Occluded
Coronaries for cardiogenic shocK (SHOCK) trial is the most important treatment strategy in CS …

… cardiogenic shock. Despite early revascularization the mortality of cardiogenic shock remains
… -based scientific knowledge in the cardiogenic shock setting. Therefore, recommendations …

… had shock due to predominant pump failure (non-mechanical aetiology). The aetiology, patient
profile, and clinical characteristics of cardiogenic shock … Conclusions Cardiogenic shock …

… from randomised clinical trials in cardiogenic shock in the PCI era. … cardiogenic shock -
including various causes of cardiogenic … EURO-SHOCK: VA-ECMO versus control in cardiogenic …

… treatment of acute and chronic heart failure 2012 of the European society of cardiology.
Developed in collaboration with the heart failure association (HFA) of the ESC. Eur J Heart Fail. …

… Cardiogenic shock (CS) is typically a consequence of an … especially in Europe after the
publication of the IABP-SHOCK II … trial in pVAD in cardiogenic shock outside cardiac arrest was …

… for patients with cardiogenic shock complicating myocardial infarction. The class of
recommendation and level of evidence according to the most recent European Society of Cardiology …

Effective management of cardiogenic shock (CS) is hampered by a lack of evidence-based
information. This is a high-mortality condition, without clear, evidence-based guidelines for …

… and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC).
Developed with the special contribution of the Heart Failure Association (HFA) of the ESC …